Who are Dendritic cell immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 10RAC+acetylcystein, AV-GBM-1, GLSI-100, SV-BR-1-GM, Lucanix™.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dendritic-cell-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Dendritic cell immunotherapy — Competitive Intelligence Brief

Dendritic cell immunotherapy (Dendritic cell immunotherapy) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dendritic cell vaccine. Area: Oncology.

phase 3 Dendritic cell vaccine Oncology Biologic Live · refreshed every 30 min

Target snapshot

Dendritic cell immunotherapy (Dendritic cell immunotherapy) — PT. JES Kasih Nusantara Sejahterah. Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dendritic cell immunotherapy TARGET	Dendritic cell immunotherapy	PT. JES Kasih Nusantara Sejahterah	phase 3	Dendritic cell vaccine
10RAC+acetylcystein	10RAC+acetylcystein	Buddhist Tzu Chi General Hospital	marketed	Dendritic cell vaccine with antioxidant adjuvant
AV-GBM-1	AV-GBM-1	Aivita Biomedical, Inc.	phase 3	Autologous dendritic cell vaccine
GLSI-100	GLSI-100	Greenwich LifeSciences, Inc.	phase 3	Dendritic cell vaccine	HER2 and other tumor-associated antigens
SV-BR-1-GM	SV-BR-1-GM	BriaCell Therapeutics Corporation	phase 3	Autologous dendritic cell vaccine	Breast cancer-associated antigens (patient-specific)
Lucanix™	Lucanix™	NovaRx Corporation	phase 3	Dendritic cell vaccine	PRAME (Preferentially Expressed Antigen in Melanoma)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dendritic cell vaccine class)

Greenwich LifeSciences, Inc. · 1 drug in this class
NovaRx Corporation · 1 drug in this class
PT. JES Kasih Nusantara Sejahterah · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dendritic cell immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/dendritic-cell-immunotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab